AstraZeneca scores win in race to treat ovarian cancer

AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

This study provides a potential therapeutic target for ovarian cancer.
Source: Life Sciences - Category: Biology Source Type: research
Publication date: Available online 25 July 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Raseen Tariq, Page Axley, Ashwani K. SingalNonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease worldwide with a strong association with metabolic syndrome. NAFLD is truly a systemic disease and is associated with a plethora of extra-hepatic manifestations or comorbidities. These are either related to secondary effects of associated obesity or from pathophysiological effects of insulin resistance in NAFLD. Three most common causes of increased morbidity and mortality associa...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
In conclusion, our data show how oncogenic and tumor-suppressive drivers of cellular senescence act to regulate surveillance processes that can be circumvented to enable SnCs to elude immune recognition but can be reversed by cell surface-targeted interventions to purge the SnCs that persist in vitro and in patients. Since eliminating SnCs can prevent tumor progression, delay the onset of degenerative diseases, and restore fitness; since NKG2D-Ls are not widely expressed in healthy human tissues and NKG2D-L shedding is an evasion mechanism also employed by tumor cells; and since increasing numbers of B cells express NKG2D ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: December 2019Source: Materials Science and Engineering: C, Volume 105Author(s): Rebeca T. Steipel, Matthew D. Gallovic, Cole J. Batty, Eric M. Bachelder, Kristy M. AinslieAbstractAlso known as electrospray, electrohydrodynamic atomization has been used extensively in the last 15 years to develop polymer-based particles for drug delivery in cell and animal models. More recently, novel core-shell, multi-axial, and other electrospray particles have been developed from an array of polymers for a variety of biomedical applications. This review focuses on electrospray as a novel method of particle fabrication...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
ConclusionInitial tumor load has not been found associated with PFS after complete surgery. Adipocytes-enriched areas and right mesocolic areas involvement were associated with poor prognosis in patients receiving primary debulking surgery. Larger-scale studies are needed to assess whether initial tumor load has a prognostic impact even after complete cytoreductive surgery is achieved.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: Available online 16 August 2019Source: Pathology - Research and PracticeAuthor(s): Ahwon Lee, Jun Kang, Hyung-Nam Lee, Yun Soo Lee, Youn Jin Choi, Keun Ho Lee, Goutam J Nistala, Charles R. Scafe, Jongpill Choi, Jaeeun Yoo, Eunhee Han M.D, Yonggoo Kim, Myungshin KimAbstractIntroductionThe detection of BRCA1/2 mutations is important because PARP1 inhibitors are approved for germline and/or somatic BRCA-mutated advanced ovarian cancer. Next-generation sequencing (NGS) is increasingly used in clinical practice for BRCA1/2 mutations. To consider several conditions of NGS BRCA1/2 assay applicable to clinical la...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Virginia Public Radio does a nice job describing how Kathy Brandt used social media to share her dying from ovarian cancer. The compelling story has also been nicely covered by Kaiser Health News and others.
Source: - Category: Medical Ethics Authors: Tags: Health Care syndicated Source Type: blogs
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Background: Ovarian cancer (OvC) is a malignant tumor invade ovarian epithelium and interstitium. Reduction surgery combined with adjuvant chemotherapy is standard treatment for OvC patients, but adverse effects due to chemotherapy still remain a major problem. While Chinese herbal medicine (CHM) therapy has an unique therapeutic effect to reduce side effects of chemotherapy by boosting immune system, but the evidence of CHM to treat these OvC patients are limited. Objective: We conducted systematic review to evaluate the efficacy and safety of CHM in the treatment of OvC after reduction surgery and adjuvant chemotherapy....
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.Resumo Objetivo Descrever uma s érie de casos de tumores de células de Sertoli-Leydig (TCSLs) ovarianos. Métodos Revisão retrospectiva de 12 casos de TCSL tratados no Hospital de Câncer de Barretos entre outubro de 2009 e agosto de 2017. Resultados A mediana de idade foi 31 anos (15-71 anos). Um total de 9 pacientes (75,0 %) apres...
Source: Revista Brasileira de Ginecologia e Obstetricia - Category: OBGYN Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Health | Ovarian Cancer | Ovaries